{"id":768809,"date":"2023-07-11T06:25:18","date_gmt":"2023-07-11T10:25:18","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/immuron-business-update-ateria-health-launches-juvia-in-australia\/"},"modified":"2023-07-11T06:25:18","modified_gmt":"2023-07-11T10:25:18","slug":"immuron-business-update-ateria-health-launches-juvia-in-australia","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/immuron-business-update-ateria-health-launches-juvia-in-australia\/","title":{"rendered":"Immuron Business Update &#8211; Ateria Health launches Juvia\u2122 in Australia"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">\n        <strong><br \/>\n          <em>Highlights:<\/em><br \/>\n        <\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">\n          <strong>Ateria has launched Juvia\u2122 containing breakthrough natural ingredient ERME\u2122 in Australia<\/strong>\n        <\/li>\n<li style=\"text-align:justify\">\n          <strong>New clinical study is underway with the NHS in Swansea, Wales in people diagnosed with IBS due to malfermentation of carbohydrates in the gut.<\/strong>\n        <\/li>\n<\/ul>\n<p align=\"justify\">MELBOURNE, Australia, July  11, 2023  (GLOBE NEWSWIRE) &#8212; Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is pleased to announce that Ateria Health Australia Pty Ltd, a subsidiary of Ateria Health Limited (\u201cAteria\u201d), has launched Juvia\u2122 in Australia.<\/p>\n<p align=\"justify\">Immuron completed settlement of a strategic investment in Ateria on 16 November 2022 (17.5% shareholding). Ateria is a UK based biotech company that develops and distributes supplements for overall health, including products that strengthen the gut microbiome.<\/p>\n<p align=\"justify\">In response to shareholder requests for an update on Ateria activities, the Company is sharing the pertinent parts of an update recently provided to Ateria shareholders by Ateria\u2019s CEO, Neil Wickers:<\/p>\n<p align=\"justify\">\n        <em>\u201cOur first brand Juvia\u2122 launched in the UK last year targeting people who suffer from irritable bowel syndrome (IBS). It contains our breakthrough patent pending natural ingredient ERME\u2122. We are selling direct to consumer via our website <\/em><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=K_mYVuUojyh9Wcb4sGWOp0mCZ8a194aWfj5aARA7AD3nIebbsunrPysn6882q5P_EpwYpK_OA7EsC9h2uo9UEA==\" rel=\"nofollow noopener\" target=\"_blank\"><br \/>\n          <em>www.juvia.me<\/em><br \/>\n        <\/a><br \/>\n        <em>. The consumer response has been phenomenal, and we have received 100\u2019s of life changing testimonials. On <\/em><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=iciTUlxT1hO6xAFoClcrAi9Qe4b1MBJt-U57xyQeuf48N9LlUBWUcFUgYf0nZghiws-OETu-FULOLaU8C20JwSrSwOjP5jtMap3VQCp3KTI=\" rel=\"nofollow noopener\" target=\"_blank\"><br \/>\n          <em>our page<\/em><br \/>\n        <\/a><br \/>\n        <em> of the independent review site Trustpilot, we are rated \u201cexcellent\u201d and the leading UK lifestyle magazine has awarded us their reader recommended accreditation. We are seeing sales in the UK grow month-on-month and we are pleased with the momentum. We continually refine our digital marketing strategy, and we now have a much deeper understanding of how to identify, attract and convert target customers.<\/em>\n      <\/p>\n<p align=\"justify\">\n        <strong><br \/>\n          <em>Juvia\u2122 Australia<\/em><br \/>\n        <\/strong>\n      <\/p>\n<p align=\"justify\">\n        <em>We are excited to announce we are launching in Australia this week. Our Australian website <\/em><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=K_mYVuUojyh9Wcb4sGWOp52sRZq_331oDN8RpvBSqyJEB7RUTZDhswe4HFMl8fyRfI-r6kC0XIru7NeRcuNOYw==\" rel=\"nofollow noopener\" target=\"_blank\"><br \/>\n          <em>www.juvia.me<\/em><br \/>\n        <\/a><br \/>\n        <em> is now live and we are fulfilling orders with free standard shipping from our logistics partner in Melbourne. Given that we have a loyal following in Australia with many ordering via our UK site we expect sales to inform our Australian launch. We will be supporting launch with Google advertising, social media advertising on Facebook, Instagram and TikTok and PR in local and national media.<\/em>\n      <\/p>\n<p align=\"justify\">\n        <strong><br \/>\n          <em>New Clinical Study Underway<\/em><br \/>\n        <\/strong>\n      <\/p>\n<p align=\"justify\">\n        <em>We now have 14 studies on ERME\u2122 in humans, horses, dogs and birds all showing consistent results. We have shown that ERME\u2122 improves the diversity of the microbiome (improving its capability and resilience), increases good bacteria (particularly those that produce butyrate, which is important for the cells of the gut wall, as well as those that have an anti-inflammatory response), reduces toxins and improves symptoms of IBS.<\/em>\n      <\/p>\n<p align=\"justify\">\n        <em>Our latest study is with the NHS in Swansea, Wales, and will look at people diagnosed with IBS due to malfermentation of carbohydrates in the gut. The first patients have been recruited and results should be available later this year.<\/em>\n      <\/p>\n<p align=\"justify\">\n        <em>We are also in the planning stages for an observational study in Melbourne later this year with Dr Harry Frydenberg, one of Australia\u2019s leading gastric surgeons, as Principal Investigator.\u201d<\/em>\n      <\/p>\n<p align=\"justify\">Immuron continues to develop plans for launch of Travelan<sup>\u00ae<\/sup> in UK \/ Europe including regulatory pathways, options for label claims, import requirements, distribution requirements and supply chain planning. Ateria is launching Juvia\u2122 in Australia direct to consumer under the Australia New Zealand Food Standards Code. Immuron is assisting Ateria with evaluating the requirements for including Juvia\u2122 in the Australian Register of Therapeutic Goods as a complementary medicine. This is a precursor for launch of Juvia\u2122 in the pharmacy sales channel.<\/p>\n<p align=\"justify\">This release has been authorised by the directors of Immuron Limited.<\/p>\n<p align=\"justify\">\n        <strong>Contact Information:<\/strong><br \/>\n        <br \/>Steven Lydeamore<br \/>Chief Executive Officer<br \/>Ph: +61 (0)3 9824 5254<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MwRnCmi3xgEWJHMDG1VBoIh9IWBCjvidBxsme7Ta8m0ihYzAPpGTYjh0LNQVBm_B4mkB_thAFru9m0BsFt91LA==\" rel=\"nofollow noopener\" target=\"_blank\">info@immuron.com<\/a><br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Y_-GJvNVjD0U2D8dMseHgm0vfF7qsCmeDu0E3uNVpQsN4nnmv7Ksde30elrl3xRFeRw5qJN5fdL-6aVxTOm7dm4bjkirKE5AsIIH9Ws_7ywDHxXZFo84TXHXcqlBumET1TNy2u9bydSqwdIyO92ikg==\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/www.immuron.com.au\/form\/contact-us\/<\/a><\/p>\n<p align=\"justify\">\n        <strong>About Immuron<\/strong><br \/>\n        <br \/>Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases.<\/p>\n<p align=\"justify\">For more information visit: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zOedooQ5jWq_phmHfWXpgXKXjhAa81WR974952U7_2Zjom3N7_DTUCuTFza3VSbHiXdRaA-LfcQL6LOs7T-qqsY5bTJ3RqtXdT7YbyMVKnQ=\" rel=\"nofollow noopener\" target=\"_blank\">http:\/\/www.immuron.com<\/a><\/p>\n<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg3MjEzNiM1Njg1OTAxIzIwMjAyOTM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NmRjYTUxZDAtMzM1ZC00NWMxLTkxOTYtZjg5NzY5ZDIxNDI5LTEwMzE4NjU=\/tiny\/Immuron-Limited.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Highlights: Ateria has launched Juvia\u2122 containing breakthrough natural ingredient ERME\u2122 in Australia New clinical study is underway with the NHS in Swansea, Wales in people diagnosed with IBS due to malfermentation of carbohydrates in the gut. MELBOURNE, Australia, July 11, 2023 (GLOBE NEWSWIRE) &#8212; Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is pleased to announce that Ateria Health Australia Pty Ltd, a subsidiary of Ateria Health Limited (\u201cAteria\u201d), has launched Juvia\u2122 in Australia. Immuron completed settlement of a strategic investment in Ateria on 16 November 2022 (17.5% shareholding). Ateria is a UK based biotech company that develops &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immuron-business-update-ateria-health-launches-juvia-in-australia\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Immuron Business Update &#8211; Ateria Health launches Juvia\u2122 in Australia&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-768809","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Immuron Business Update - Ateria Health launches Juvia\u2122 in Australia - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immuron-business-update-ateria-health-launches-juvia-in-australia\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Immuron Business Update - Ateria Health launches Juvia\u2122 in Australia - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Highlights: Ateria has launched Juvia\u2122 containing breakthrough natural ingredient ERME\u2122 in Australia New clinical study is underway with the NHS in Swansea, Wales in people diagnosed with IBS due to malfermentation of carbohydrates in the gut. MELBOURNE, Australia, July 11, 2023 (GLOBE NEWSWIRE) &#8212; Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is pleased to announce that Ateria Health Australia Pty Ltd, a subsidiary of Ateria Health Limited (\u201cAteria\u201d), has launched Juvia\u2122 in Australia. Immuron completed settlement of a strategic investment in Ateria on 16 November 2022 (17.5% shareholding). Ateria is a UK based biotech company that develops &hellip; Continue reading &quot;Immuron Business Update &#8211; Ateria Health launches Juvia\u2122 in Australia&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/immuron-business-update-ateria-health-launches-juvia-in-australia\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-11T10:25:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg3MjEzNiM1Njg1OTAxIzIwMjAyOTM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuron-business-update-ateria-health-launches-juvia-in-australia\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuron-business-update-ateria-health-launches-juvia-in-australia\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Immuron Business Update &#8211; Ateria Health launches Juvia\u2122 in Australia\",\"datePublished\":\"2023-07-11T10:25:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuron-business-update-ateria-health-launches-juvia-in-australia\\\/\"},\"wordCount\":662,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuron-business-update-ateria-health-launches-juvia-in-australia\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg3MjEzNiM1Njg1OTAxIzIwMjAyOTM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuron-business-update-ateria-health-launches-juvia-in-australia\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuron-business-update-ateria-health-launches-juvia-in-australia\\\/\",\"name\":\"Immuron Business Update - Ateria Health launches Juvia\u2122 in Australia - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuron-business-update-ateria-health-launches-juvia-in-australia\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuron-business-update-ateria-health-launches-juvia-in-australia\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg3MjEzNiM1Njg1OTAxIzIwMjAyOTM=\",\"datePublished\":\"2023-07-11T10:25:18+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuron-business-update-ateria-health-launches-juvia-in-australia\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuron-business-update-ateria-health-launches-juvia-in-australia\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuron-business-update-ateria-health-launches-juvia-in-australia\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg3MjEzNiM1Njg1OTAxIzIwMjAyOTM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg3MjEzNiM1Njg1OTAxIzIwMjAyOTM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuron-business-update-ateria-health-launches-juvia-in-australia\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Immuron Business Update &#8211; Ateria Health launches Juvia\u2122 in Australia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Immuron Business Update - Ateria Health launches Juvia\u2122 in Australia - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/immuron-business-update-ateria-health-launches-juvia-in-australia\/","og_locale":"en_US","og_type":"article","og_title":"Immuron Business Update - Ateria Health launches Juvia\u2122 in Australia - Market Newsdesk","og_description":"Highlights: Ateria has launched Juvia\u2122 containing breakthrough natural ingredient ERME\u2122 in Australia New clinical study is underway with the NHS in Swansea, Wales in people diagnosed with IBS due to malfermentation of carbohydrates in the gut. MELBOURNE, Australia, July 11, 2023 (GLOBE NEWSWIRE) &#8212; Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is pleased to announce that Ateria Health Australia Pty Ltd, a subsidiary of Ateria Health Limited (\u201cAteria\u201d), has launched Juvia\u2122 in Australia. Immuron completed settlement of a strategic investment in Ateria on 16 November 2022 (17.5% shareholding). Ateria is a UK based biotech company that develops &hellip; Continue reading \"Immuron Business Update &#8211; Ateria Health launches Juvia\u2122 in Australia\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/immuron-business-update-ateria-health-launches-juvia-in-australia\/","og_site_name":"Market Newsdesk","article_published_time":"2023-07-11T10:25:18+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg3MjEzNiM1Njg1OTAxIzIwMjAyOTM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuron-business-update-ateria-health-launches-juvia-in-australia\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuron-business-update-ateria-health-launches-juvia-in-australia\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Immuron Business Update &#8211; Ateria Health launches Juvia\u2122 in Australia","datePublished":"2023-07-11T10:25:18+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuron-business-update-ateria-health-launches-juvia-in-australia\/"},"wordCount":662,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuron-business-update-ateria-health-launches-juvia-in-australia\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg3MjEzNiM1Njg1OTAxIzIwMjAyOTM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuron-business-update-ateria-health-launches-juvia-in-australia\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/immuron-business-update-ateria-health-launches-juvia-in-australia\/","name":"Immuron Business Update - Ateria Health launches Juvia\u2122 in Australia - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuron-business-update-ateria-health-launches-juvia-in-australia\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuron-business-update-ateria-health-launches-juvia-in-australia\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg3MjEzNiM1Njg1OTAxIzIwMjAyOTM=","datePublished":"2023-07-11T10:25:18+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuron-business-update-ateria-health-launches-juvia-in-australia\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/immuron-business-update-ateria-health-launches-juvia-in-australia\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuron-business-update-ateria-health-launches-juvia-in-australia\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg3MjEzNiM1Njg1OTAxIzIwMjAyOTM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg3MjEzNiM1Njg1OTAxIzIwMjAyOTM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuron-business-update-ateria-health-launches-juvia-in-australia\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Immuron Business Update &#8211; Ateria Health launches Juvia\u2122 in Australia"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/768809","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=768809"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/768809\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=768809"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=768809"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=768809"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}